Transarterial chemoembolisation in the treatment of patients with metastatic colorectal cancer

Abstract

Aim. To assess effectiveness of chemoembolization of hepatic artery (CEHA) in treatment of patients with metastatic colorectal cancer, and also to determine the optimal interval in combination of CEHA with other treatment methods.

Materials and Methods. The study includes analysis of the results of treatment of 30 patients with resectable metastases of colorectal cancer in the liver. The first group included 15 patients with resection made 1 week after CEHA. The second group consisted of 15 patients in whom resection operation was made 2 weeks after CENA with subsequent assessment of morphological changes in metastases.

Results. Therapeutic pathomorphism was recorded in 25/30 patients. In the first group, therapeutic pathomorphism was observed in 13/15 patients. In 11/13 patients, the 2^nd degree of therapeutic pathomorphism was recorded. In 2/13 patients – the 1^st degree. In the second group, therapeutic pathomorphism was observed in 12/15 patients. In all patients the 2^nd degree of therapeutic pathomorphism was recorded. No significant differences in the degree of therapeutic pathomorphism were recorded on the 7^th and 14^th day after regional chemotherapy (p=0.436).

Conclusion. Hepatic artery chemoembolization is an effective method of treating patients with metastases of colorectal cancer in the liver. In use of chemoembolization of hepatic artery in combination with other surgical methods, the sevenday time interval is optimal.

Keywords

metastases of colorectal liver cancer / regional chemotherapy / therapeutic pathomorphosis

References

[1] Petrenko KN, Polishchuk LO, Garmaeva SV, et al. Radiochastotnaya ablyaciya zlokachestvennyh novoobrazovanij pecheni. Sovremennoe sostoyanie voprosa (Obzor literatury). Rossijskij zhurnal gactroehnterologii, gepatologii, koloproktologii. 2007;2:108. (In Russ).

[2] Петренко К.Н., Полищук Л.О., Гармаева С.В., и др. Радиочастотная абляция злокачественных новообразований печени. Современное состояние вопроса (Обзор литературы) // Российский журнал гаcтроэнтерологии, гепатологии, колопроктологии. 2007. Т. 2. С. 1018.

[3] Patyutko YuI, Sagajdak IV, Polyakov AN. Kombinirovannoe lechenie bol'nyh s metastazami kolorektal'nogo raka v pechen'. Hirurgiya. Zhurnal im. NI Pirogova. 2008; 7:204. (In Russ).

[4] Патютко Ю.И., Сагайдак И.В., Поляков А.Н. Комбинированное лечение больных с метастазами колоректального рака в печень // Хирургия. Журнал им. Н.И. Пирогова. 2008. №7. С. 2024.

[5] Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Annals of Surgery. 1997;225(1):5162. doi:10. 1097/0000065819970100000006

[6] Adam R., Bismuth H., Castaing D., et al. Repeat hepatectomy for colorectal liver metastases // Annals of Surgery. 1997. Vol. 225, №1. P. 5162. doi:10.1097/0000065819970100000006

[7] Dudarev VS. Maloinvazivnye tekhnologii v lechenii zlokachestvennyh opuholej pecheni. Onkologicheskij zhurnal. 2007;1(2):12644. (In Russ).

[8] Дударев В.С. Малоинвазивные технологии в лечении злокачественных опухолей печени // Онкологический журнал. 2007. Т. 1, №2. С. 126144.

[9] Patyutko YuI. Hirurgicheskoe lechenie zlokachestvennyh opuholej pecheni. Moscow: Prakticheskaya medicina; 2005. (In Russ).

[10] Патютко Ю.И. Хирургическое лечение злокачественных опухолей печени. М.: Практическая медицина, 2005.

[11] Abdalla E, Vauthey J, Ellis L, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Annals of Surgery. 2004;239(6):81825. doi: 10.1097/01.sla.0000128305.90650.71

[12] Abdalla E., Vauthey J., Ellis L., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases // Annals of Surgery. 2004. Vol. 239, №6. P. 818825. doi:10.1097/01.sla.0000128305. 90650.71

[13] August DA, Sugarbaker PH, Schneider PD. Lymphatic dissemination of hepatic metastases. Implications for the follow‐up and treatment of patients with colorectal cancer. Cancer. 1985;55 (7):14904. doi:10.1002/10970142(19850401) 55:7<1490 ::aidcncr2820550712>3.0.co;2n

[14] August D.A., Sugarbaker P.H., Schneider P.D. Lymphatic dissemination of hepatic metastases. Implications for the follow‐up and treatment of patients with colorectal cancer // Cancer. 1985. Vol. 55, №7. P. 14901494. doi: 10. 1002/10970142(19850401)55:7<1490::aidcncr2820550712>3.0.co;2n

[15] Agcaoglu O, Aliyev S, Karabulut K, et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World Journal of Surgery. 2013;37(6):13339. doi:10.1007/s0026801319811

[16] Agcaoglu O., Aliyev S., Karabulut K., et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients // World Journal of Surgery. 2013. Vol. 37, №6. P. 13331339. doi: 10.1007/s0026801319811

[17] Kim K, Yoon Y, Yu C, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. Journal of the Korean Surgical Society. 2011; 81(1):2534. doi:10.4174/jkss.2011. 81.1.25

[18] Kim K., Yoon Y., Yu C., et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases // Journal of the Korean Surgical Society. 2011. Vol. 81, №1. P. 2534. doi:10.4174/jkss.2011.81.1.25

[19] Solbiati L, Ahmed M, Cova L, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and longterm survival with up to 10year followup. Radiology. 2012;265(3): 95868. doi:10.1148/radiol.12111851

[20] Solbiati L., Ahmed M., Cova L., et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and longterm survival with up to 10year followup // Radiology. 2012. Vol. 265, №3. P. 958968. doi:10.1148/radiol.12111851

[21] Wood T, Rose D, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Annals of Surgical Oncology. 2000; 7(8):593600. doi:10.1007/bf02725339

[22] Wood T., Rose D., Chung M., et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications // Annals of Surgical Oncology. 2000. Vol. 7, №8. P. 593600. doi:10.1007/bf02725339

[23] Lin J, Wu W, Jiang X, et al. Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a singlecenter experience. Chinese Journal of Oncology. 2013;35(2):1447. doi:10.3760/cma. j.issn.02533766.2013.02.016

[24] Lin J., Wu W., Jiang X., et al. Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a singlecenter experience // Chinese Journal of Oncology. 2013. Vol. 35, №2. P. 144147. doi:10.3760/cma.j.issn.02533766.2013.02.016

[25] Tanaka M, Ando E, Simose S, et al. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatology Research. 2014; 44(2):194200. doi:10.1111/ hepr.12100

[26] Tanaka M., Ando E., Simose S., et al. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma // Hepatology Research. 2014. Vol. 44, №2. P. 194200. doi:10.1111/hepr.12100

[27] Duan X, Zhou G, Zheng C, et al. Heat shock protein 70 expression and effect of combined transcatheter arterial embolization and radiofrequency ablation in the rabbit VX2 liver tumour model. Clinical Radiology. 2014;69(2): 18693. doi:10.1016/j.crad.2013. 08.020

[28] Duan X., Zhou G., Zheng C., et al. Heat shock protein 70 expression and effect of combined transcatheter arterial embolization and radiofrequency ablation in the rabbit VX2 liver tumour model // Clinical radiology. 2014. Vol. 69, №2. P. 186193. doi:10.1016/j.crad.2013.08.020

[29] Duan X, Li T, Zhou G, et al. Transcatheter arterial embolization combined with radiofrequency ablation activates cD8+ Tcell infiltration surrounding residual tumors in the rabbit VX2 liver tumors. Onco Targets and Therapy. 2016;9:283544. doi:10.2147/ OTT.S95973

[30] Duan X., Li T., Zhou G., et al. Transcatheter arterial embolization combined with radiofrequency ablation activates cD8+ Tcell infiltration surrounding residual tumors in the rabbit VX2 liver tumors // Onco Targets and Therapy. 2016. Vol. 9. P. 28352834. doi:10.2147/OTT.S95973

[31] Lu Z, Wen F, Guo Q, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a metaanalysis of randomizedcontrolled trials. European Journal of Gastroenterology & Hepatology. 2013;25(2): 18794. doi:10.1097/MEG.0b013e32835a0a07

[32] Lu Z., Wen F., Guo Q., et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a metaanalysis of randomizedcontrolled trials // European Journal of Gastroenterology&Hepatology. 2013. Vol. 25, №2. P. 187194. doi:10.1097/MEG.0b013e32835a0a07

[33] Tang C, Shen J, Feng W, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma: a retrospective study. Medicine. 2016;95(20):375461. doi:10. 1097/MD.0000000000003754

[34] Tang C., Shen J., Feng W., et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma: a retrospective study // Medicine. 2016. Vol. 95, №20. P. 3754. doi:10.1097/MD.0000000000003754

[35] Li Z, Kang Z, Qian J, et al. Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma. Journal of Southern Medical University. 2007;27(11):174951.

[36] Li Z., Kang Z., Qian J., et al. Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma // Journal of Southern Medical University. 2007. Vol. 27, №11. P. 17491751.

[37] Song M, Bae S, Lee J, et al. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. The Korean Journal of Internal Medicine. 2016;31(2):24252. doi:10.3904/kjim. 2015.112

[38] Song M., Bae S., Lee J., et al. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma // The Korean journal of internal medicine. 2016. Vol. 31, №2. P. 242252. doi: 10.3904/kjim.2015.112

[39] Zhang L, Yon X, Gan Y, et al. Radiofrequency ablation following firstline transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria. BMC Gastroenterology. 2014;14(1):118. doi:10.1186/ 1471230X1411

[40] Zhang L., Yon X., Gan Y., et al. Radiofrequency ablation following firstline transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria // BMC Gastroenterology. 2014. Vol. 14, №1. P. 1118. doi:10.1186/1471230X1411

[41] Wang Z, Wang M, Duan F, et al. Transcatheter arterial chemoembolization followed by immediate radiofrequency ablation for large solitary hepatocellular carcinomas. World Journal of Gastroenterology. 2013;19(26): 41929. doi:10.3748/wjg.v19. i26.4192

[42] Wang Z., Wang M., Duan F., et al. Transcatheter arterial chemoembolization followed by immediate radiofrequency ablation for large solitary hepatocellular carcinomas // World Journal of Gastroenterology. 2013. Vol. 19, №26. P. 41924199. doi:10.3748/wjg.v19.i26.4192

RIGHTS & PERMISSIONS

Shabunin A.V., Tavobilov M.M., Paklina O.V., Grekov D.N., Setdikova G.R., Drozdov P.A.